Significance of Programmed Cell Death-Ligand 1 Expression and its Association with Survival in Patients with Small Cell Lung Cancer. Issue 3 (March 2015)
- Record Type:
- Journal Article
- Title:
- Significance of Programmed Cell Death-Ligand 1 Expression and its Association with Survival in Patients with Small Cell Lung Cancer. Issue 3 (March 2015)
- Main Title:
- Significance of Programmed Cell Death-Ligand 1 Expression and its Association with Survival in Patients with Small Cell Lung Cancer
- Authors:
- Ishii, Hidenobu
Azuma, Koichi
Kawahara, Akihiko
Yamada, Kazuhiko
Imamura, Yohei
Tokito, Takaaki
Kinoshita, Takashi
Kage, Masayoshi
Hoshino, Tomoaki - Abstract:
- Abstract : Background: Programmed cell death 1 receptor–ligand interaction is a major pathway often hijacked by tumors to suppress immune control. The aim of this retrospective study was to investigate the prevalence and prognostic roles of programmed cell death -ligand 1 (PD-L1) expression in small cell lung cancer (SCLC). Methods: The expression of PD-L1 was evaluated by immunohistochemical analysis in 102 specimens of SCLC. Tumors with staining in over 5% of tumor cells were scored as positive for PD-L1 expression. Survival analysis was performed using the Kaplan–Meier method. Results: Expression of PD-L1 in tumor cells was observed in 71.6% (73 of 102) of SCLCs, and was significantly correlated with a limited disease (LD) stage. SCLC patients with PD-L1-positive tumors showed significantly longer overall survival (OS) than those with PD-L1-negative (median OS, 16.3 versus 7.3 months; p < 0.001, respectively). Multivariate analyses demonstrated that a good performance status, LD stage, and expression of PD-L1 were significantly predictive of better OS, independently of other factors. We found no relevance between PD-L1 expression and progression-free survival for first-line treatment in LD- and extensive disease-SCLC patients. Conclusions: In patients with SCLC, expression of PD-L1 is positively correlated with a LD stage, and is independently predictive of a favorable outcome.
- Is Part Of:
- Journal of thoracic oncology. Volume 10:Issue 3(2015)
- Journal:
- Journal of thoracic oncology
- Issue:
- Volume 10:Issue 3(2015)
- Issue Display:
- Volume 10, Issue 3 (2015)
- Year:
- 2015
- Volume:
- 10
- Issue:
- 3
- Issue Sort Value:
- 2015-0010-0003-0000
- Page Start:
- Page End:
- Publication Date:
- 2015-03
- Subjects:
- Small cell lung cancer -- PD-L1 -- Immunohistochemistry -- Prognostic factor
Chest -- Cancer -- Periodicals
Thoracic Neoplasms -- Periodicals
616.99494005 - Journal URLs:
- http://gateway.ovid.com/ovidweb.cgi?T=JS&MODE=ovid&NEWS=n&PAGE=toc&D=ovft&AN=01243894-000000000-00000 ↗
http://gateway.ovid.com/ovidweb.cgi?T=JS&MODE=ovid&PAGE=toc&D=ovft&AN=01243894-200601000-00001 ↗
http://www.sciencedirect.com/science/journal/15560864/ ↗
http://journals.lww.com/pages/default.aspx ↗ - DOI:
- 10.1097/JTO.0000000000000414 ↗
- Languages:
- English
- ISSNs:
- 1556-0864
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 5069.124000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 6383.xml